Aurinia Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AUPH Nasdaq 2836 www.auriniapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aurinia Pharmaceuticals Inc.

Aurinia (AUPH) Upgraded to Buy: Here's Why - Jan 22nd, 2025 5:00 pm
Exploring Three High Growth Tech Stocks In The United States - Dec 11th, 2024 6:03 pm
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - Dec 10th, 2024 1:30 pm
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Dec 6th, 2024 2:54 pm
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Nov 18th, 2024 10:53 pm
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - Nov 15th, 2024 11:00 am
Aurinia to Participate in Jefferies London Healthcare Conference - Nov 14th, 2024 11:00 am
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Nov 8th, 2024 3:30 pm
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Nov 8th, 2024 7:12 am
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - Nov 7th, 2024 12:40 pm
Aurinia: Q3 Earnings Snapshot - Nov 7th, 2024 11:41 am
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Nov 7th, 2024 11:10 am
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - Nov 7th, 2024 11:00 am
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago - Nov 2nd, 2024 2:36 pm
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - Oct 30th, 2024 8:05 pm
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 - Oct 11th, 2024 10:00 am
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability - Sep 27th, 2024 12:47 pm
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis - Sep 24th, 2024 12:10 pm
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference - Sep 13th, 2024 10:00 am
Aurinia Announces Board Restructuring - Sep 12th, 2024 8:05 pm